Risk of colorectal cancer following adenoma removal – SAR

The increasing use of colonoscopy both for examination of symptomatic and for screening purposes entails detection of a large number of patients with adenomas in the colon and the rectum. The majority of these lesions, widely considered to be precursors of colorectal cancer, can be removed during colonoscopy. There is a wide-spread perception that these individuals are at increased risk of developing new precursors and in the long-term at increased risk of developing also invasive cancer. Based on features of the removed lesion, they are classified – according to different algorithms – into low and high, sometime even intermediate risk lesions and subjected to various follow-up regimen. However, the fundamental challenge is to properly quantify the excess risk of colorectal cancer, if any, following adenoma removal. Based on results from Norway that we published in 2014 (Løberg M, Kalager M, Holme O, Hoff G, Adami HO, Bretthauer M. Long-term colorectal cancer mortality after adenoma removal. N Engl J Med 2014;371:799-807) this risk might have been exaggerated particularly among patients with low risk adenomas. However, in order to confirm or refute the findings from Norway, a large-scale study in Sweden is currently in progress. Our plan is to enroll a large number of patients who have had adenomas removed and follow them through record linkages in order to quantify their subsequent risk of colorectal cancer. In a second step, we also plan a nested case-control study (cases being patients who develop cancer following adenoma removal and control samples of those who did not develop cancer). In this study, we will retrieve much more detailed information from hospital records and pathology reports. We except results from the cohort analyses to be finalized and submitted for publication sometime during 2016.

Participants: Hans-Olov Adami (PI), Louise Emilsson (Project Leader), Katja Fall

Collaborators in Norway: Mette Kalager, Michael Bretthauer, Magnus LØberg

Financing: The Swedish Cancer Society, The Research Council of Norway

Contact information

Professor emeritus

Hans-Olov Adami

Phone: +46-(0)8-524 861 80
E-mail: Hans-Olov.Adami@ki.se


Katja Fall

E-mail: katja.fall@ki.se

Cancer and OncologyEpidemiology